I don't think we should be leveling blame at anyone as we don't really know the inner workings of the company and the whole business model, as well as the obstacles to get sales. Sure, having Sozo recommended in the NCCN guidelines for lymphedema helps but to actually see sales increase could take some time under any management.
Ann: Quarterly Activities Report and Appendix 4C - Dec-23 Qtr, page-207
Add IPD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.4¢ |
Change
0.004(5.00%) |
Mkt cap ! $169.9M | |||
| Open | High | Low | Value | Volume |
| 8.1¢ | 8.4¢ | 8.0¢ | $256.5K | 3.159M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 200000 | 8.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.5¢ | 121194 | 2 |
View Market Depth
| Last trade - 16.10pm 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
8.3¢ |
Change
0.004 ( 3.75 %) |
||||
| Open | High | Low | Volume | ||
| 8.2¢ | 8.4¢ | 7.9¢ | 1002631 | ||
| Last updated 15.59pm 15/05/2024 ? | |||||
| IPD (ASX) Chart |